Stipple Bio launches with $100M to find more precise targets on cancer proteins
Stipple Bio获1亿美元启动资金，致力于寻找癌症蛋白上更精确的靶点

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples).
众所周知，癌症药物研发充满“跟风”。一旦出现一个看好的靶点，各家公司便一拥而上（近期的例子包括PD‑1×VEGF或HER2）。